ຂໍ້ມູນເພີ່ມເຕີມ ― Lao

Keratoacanthoma (KA) ເປັນເນື້ອງອກຕາມຜິວໜັງເລື້ອຍໆ ທີ່ຮູ້ຈັກກັບການຂະຫຍາຍຕົວໄວ ແລະ ມີທ່າແຮງທີ່ຈະກັບຄືນມາໄດ້ດ້ວຍຕົວມັນເອງ. ໂດຍປົກກະຕິແລ້ວມັນເກີດຂຶ້ນໃນຜູ້ຊາຍທີ່ມີອາຍຸແກ່, ຜິວພັນທີ່ຍຸຕິທໍາທີ່ມີປະຫວັດຄວາມເສຍຫາຍຈາກແສງແດດ. ໃນຂະນະທີ່ການໂຍກຍ້າຍການຜ່າຕັດໂດຍໃຊ້ການຜ່າຕັດແບບຕັດອອກຫຼື Mohs micrographic ແມ່ນການປິ່ນປົວແບບປົກກະຕິ, ມີທາງເລືອກການປິ່ນປົວອື່ນໆທີ່ມີຢູ່.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.

Keratoacanthoma (KA) ເປັນເນື້ອງອກລະດັບຕໍ່າທີ່ເລີ່ມຢູ່ໃນຕ່ອມບາງອັນໃນຜິວໜັງ ແລະມີລັກສະນະຄ້າຍກັບ squamous cell carcinoma (SCC) ພາຍໃຕ້ກ້ອງຈຸລະທັດ. ມີການໂຕ້ວາທີຢ່າງຕໍ່ເນື່ອງກ່ຽວກັບວ່າ KA ຄວນຖືກຈັດເປັນຮູບແບບຂອງ SCC ທີ່ຮຸກຮານຫຼືບໍ່.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.

Cutaneous squamous cell carcinoma (cSCC) ເປັນມະເຮັງຊະນິດທີ 2 ທີ່ພົບເລື້ອຍໃນຄົນ ໂດຍສະເພາະຜູ້ສູງອາຍຸ. ການຜ່າຕັດແມ່ນຖືກນໍາໃຊ້ໂດຍປົກກະຕິເພື່ອປິ່ນປົວ cSCC, ແຕ່ສໍາລັບຄົນເຈັບບາງຄົນທີ່ບໍ່ສາມາດຜ່າຕັດຫຼືເລືອກທີ່ຈະບໍ່, ທາງເລືອກອື່ນເຊັ່ນການປິ່ນປົວ intralesional ສາມາດພິຈາລະນາ. ການປິ່ນປົວ intralesional ແບບດັ້ງເດີມ (methotrexate or 5-fluorouracil) ໄດ້ຖືກນໍາໃຊ້, ແຕ່ມີການຄົ້ນຄວ້າຢ່າງຕໍ່ເນື່ອງກ່ຽວກັບວິທີການໃຫມ່ເຊັ່ນ immunotherapy intralesional ແລະການປິ່ນປົວດ້ວຍ virotherapy oncolytic. ໃນທີ່ນີ້, ພວກເຮົາຈະເບິ່ງການປິ່ນປົວ intralesional ທີ່ແຕກຕ່າງກັນສໍາລັບ cSCC, ຕັ້ງແຕ່ວິທີການຄລາສສິກຈົນເຖິງຍຸດທະສາດທີ່ທັນສະ ໄໝ.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.